North America Cephalosporin Drugs Market (2019-2025)
The North America Cephalosporin Drugs Market would witness market growth of 4.69% CAGR during the forecast period (2019–2025). Market growth is driven by the implementation of combination drugs like various antibacterials or antibacterials coupled with an inhibitor. It is anticipated that the use of combination drugs will reduce the likelihood of developing antibiotic-resistant bacterial strains, which is supposed to boost the market growth.
Compared to the first and second generations, Cephalosporin Drugss of the third generation are more efficient against Gram-negative bacteria. They are also more effective against bacteria that can be resistant to prior Cephalosporin Drugs generations. Cefepime (Maxipime) is the only Cephalosporin Drugs of the fourth generation accessible in the U.S. Although it is efficient against a multitude of Gram-positive and Gram-negative organisms, it is generally reserved for more serious diseases. The fifth-generation Cephalosporin Drugs, ceftaroline (Teflaro) may be used to treat bacteria that are resistant to penicillin antibiotics, including resistant species Staphylococcus aureus (MRSA) and Streptococcus.
Based on Generation, the market is segmented into First-Generation Cephalosporin, Second-Generation Cephalosporin, Third-Generation Cephalosporin, Fourth-Generation Cephalosporin, and Fifth-Generation Cephalosporin. Based on Application, the market is segmented into Respiratory Tract Infection, Skin Infection, Ear Infection, Sexually Transmitted Infection and Others. Based on Route of Administration, the market is segmented into Injections and Oral Drugs. Based on Type, the market is segmented into Branded and Generic. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include ABBOTT Laboratories, Teva Pharmaceuticals Industries Ltd., Johnson and Johnson, GlaxoSmithKline PLC (GSK), Pfizer, Inc., Merck & Co., Inc., Bayer AG, Baxter International, Inc., Bristol-Myers Squibb Company and Novartis AG.
Scope of the Study
Market Segmentation:
By Generation
Compared to the first and second generations, Cephalosporin Drugss of the third generation are more efficient against Gram-negative bacteria. They are also more effective against bacteria that can be resistant to prior Cephalosporin Drugs generations. Cefepime (Maxipime) is the only Cephalosporin Drugs of the fourth generation accessible in the U.S. Although it is efficient against a multitude of Gram-positive and Gram-negative organisms, it is generally reserved for more serious diseases. The fifth-generation Cephalosporin Drugs, ceftaroline (Teflaro) may be used to treat bacteria that are resistant to penicillin antibiotics, including resistant species Staphylococcus aureus (MRSA) and Streptococcus.
Based on Generation, the market is segmented into First-Generation Cephalosporin, Second-Generation Cephalosporin, Third-Generation Cephalosporin, Fourth-Generation Cephalosporin, and Fifth-Generation Cephalosporin. Based on Application, the market is segmented into Respiratory Tract Infection, Skin Infection, Ear Infection, Sexually Transmitted Infection and Others. Based on Route of Administration, the market is segmented into Injections and Oral Drugs. Based on Type, the market is segmented into Branded and Generic. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include ABBOTT Laboratories, Teva Pharmaceuticals Industries Ltd., Johnson and Johnson, GlaxoSmithKline PLC (GSK), Pfizer, Inc., Merck & Co., Inc., Bayer AG, Baxter International, Inc., Bristol-Myers Squibb Company and Novartis AG.
Scope of the Study
Market Segmentation:
By Generation
- First-Generation Cephalosporin
- Second-Generation Cephalosporin
- Third-Generation Cephalosporin
- Fourth-Generation Cephalosporin
- Fifth-Generation Cephalosporin
- Respiratory Tract Infection
- Skin Infection
- Ear Infection
- Sexually Transmitted Infection
- Others
- Injections
- Oral Drugs
- Branded
- Generic
- US
- Canada
- Mexico
- Rest of North America
- ABBOTT Laboratories
- Teva Pharmaceuticals Industries Ltd.
- Johnson and Johnson
- GlaxoSmithKline PLC (GSK)
- Pfizer, Inc.
- Merck & Co., Inc.
- Bayer AG
- Baxter International, Inc.
- BRISTOL-MYERS SQUIBB COMPANY
- Novartis AG
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
CHAPTER 1. MARKET SCOPE & METHODOLOGY
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Cephalosporin Drugs Market, by Generation
1.4.2 North America Cephalosporin Drugs Market, by Application
1.4.3 North America Cephalosporin Drugs Market, by Route of Administration
1.4.4 North America Cephalosporin Drugs Market, by Type
1.4.5 North America Cephalosporin Drugs Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY GENERATION
3.1 North America First-Generation Cephalosporin Drugs Market by Country
3.2 North America Second-Generation Cephalosporin Drugs Market by Country
3.3 North America Third-Generation Cephalosporin Drugs Market by Country
3.4 North America Fourth-Generation Cephalosporin Drugs Market by Country
3.5 North America Fifth-Generation Cephalosporin Drugs Market by Country
CHAPTER 4. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY APPLICATION
4.1 North America Respiratory Tract Infection Market by Country
4.2 North America Skin Infection Market by Country
4.3 North America Ear Infection Market by Country
4.4 North America Sexually Transmitted Infection Market by Country
4.5 North America Others Market by Country
CHAPTER 5. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION
5.1 North America Injections Market by Country
5.2 North America Oral Drugs Market by Country
CHAPTER 6. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY TYPE
6.1 North America Branded Market by Country
6.2 North America Generic Market by Country
CHAPTER 7. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY COUNTRY
7.1 USA Cephalosporin Drugs Market
7.1.1 USA Cephalosporin Drugs Market by Generation
7.1.2 USA Cephalosporin Drugs Market by Application
7.1.3 USA Cephalosporin Drugs Market by Route of Administration
7.1.4 USA Cephalosporin Drugs Market by Type
7.2 Canada Cephalosporin Drugs Market
7.2.1 Canada Cephalosporin Drugs Market by Generation
7.2.2 Canada Cephalosporin Drugs Market by Application
7.2.3 Canada Cephalosporin Drugs Market by Route of Administration
7.2.4 Canada Cephalosporin Drugs Market by Type
7.3 Mexico Cephalosporin Drugs Market
7.3.1 Mexico Cephalosporin Drugs Market by Generation
7.3.2 Mexico Cephalosporin Drugs Market by Application
7.3.3 Mexico Cephalosporin Drugs Market by Route of Administration
7.3.4 Mexico Cephalosporin Drugs Market by Type
7.4 Rest of North America Cephalosporin Drugs Market
7.4.1 Rest of North America Cephalosporin Drugs Market by Generation
7.4.2 Rest of North America Cephalosporin Drugs Market by Application
7.4.3 Rest of North America Cephalosporin Drugs Market by Route of Administration
7.4.4 Rest of North America Cephalosporin Drugs Market by Type
CHAPTER 8. COMPANY PROFILES
8.1 ABBOTT Laboratories
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.1 Recent strategies and developments:
8.1.1.1 Collaborations, partnerships and agreements:
8.1.1.2 Acquisition and Mergers:
8.2 Teva Pharmaceutical Industries Ltd.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Product launches:
8.3 Johnson and Johnson
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental &Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Acquisition and Mergers:
8.4 GlaxoSmithKline PLC (GSK)
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Collaborations, partnerships and agreements:
8.4.5.2 Expansion:
8.4.5.3 Approval:
8.5 Pfizer, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Collaborations, partnerships and agreements:
8.5.5.2 Product launches:
8.5.5.3 Acquisition and Mergers:
8.6 Merck & Co., Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Collaborations, partnerships and agreements:
8.6.5.2 Product launches:
8.7 Bayer AG (Bayer Schering Pharma AG)
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 Recent strategies and developments:
8.7.5.1 Collaborations, partnerships and agreements:
8.7.5.2 Product launches:
8.8 Baxter International, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Product launches:
8.9 Bristol-Myers Squibb Company
8.9.1 Company overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expense
8.9.5 Recent strategies and developments:
8.9.5.1 Collaborations, partnerships and agreements:
8.1 Novartis AG
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Segmental and Regional Analysis
8.10.4 Research & Development Expense
8.10.5 Recent strategies and developments:
8.10.5.1 Product launches:
8.10.5.2 Acquisition and Mergers:
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Cephalosporin Drugs Market, by Generation
1.4.2 North America Cephalosporin Drugs Market, by Application
1.4.3 North America Cephalosporin Drugs Market, by Route of Administration
1.4.4 North America Cephalosporin Drugs Market, by Type
1.4.5 North America Cephalosporin Drugs Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY GENERATION
3.1 North America First-Generation Cephalosporin Drugs Market by Country
3.2 North America Second-Generation Cephalosporin Drugs Market by Country
3.3 North America Third-Generation Cephalosporin Drugs Market by Country
3.4 North America Fourth-Generation Cephalosporin Drugs Market by Country
3.5 North America Fifth-Generation Cephalosporin Drugs Market by Country
CHAPTER 4. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY APPLICATION
4.1 North America Respiratory Tract Infection Market by Country
4.2 North America Skin Infection Market by Country
4.3 North America Ear Infection Market by Country
4.4 North America Sexually Transmitted Infection Market by Country
4.5 North America Others Market by Country
CHAPTER 5. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION
5.1 North America Injections Market by Country
5.2 North America Oral Drugs Market by Country
CHAPTER 6. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY TYPE
6.1 North America Branded Market by Country
6.2 North America Generic Market by Country
CHAPTER 7. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY COUNTRY
7.1 USA Cephalosporin Drugs Market
7.1.1 USA Cephalosporin Drugs Market by Generation
7.1.2 USA Cephalosporin Drugs Market by Application
7.1.3 USA Cephalosporin Drugs Market by Route of Administration
7.1.4 USA Cephalosporin Drugs Market by Type
7.2 Canada Cephalosporin Drugs Market
7.2.1 Canada Cephalosporin Drugs Market by Generation
7.2.2 Canada Cephalosporin Drugs Market by Application
7.2.3 Canada Cephalosporin Drugs Market by Route of Administration
7.2.4 Canada Cephalosporin Drugs Market by Type
7.3 Mexico Cephalosporin Drugs Market
7.3.1 Mexico Cephalosporin Drugs Market by Generation
7.3.2 Mexico Cephalosporin Drugs Market by Application
7.3.3 Mexico Cephalosporin Drugs Market by Route of Administration
7.3.4 Mexico Cephalosporin Drugs Market by Type
7.4 Rest of North America Cephalosporin Drugs Market
7.4.1 Rest of North America Cephalosporin Drugs Market by Generation
7.4.2 Rest of North America Cephalosporin Drugs Market by Application
7.4.3 Rest of North America Cephalosporin Drugs Market by Route of Administration
7.4.4 Rest of North America Cephalosporin Drugs Market by Type
CHAPTER 8. COMPANY PROFILES
8.1 ABBOTT Laboratories
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.1 Recent strategies and developments:
8.1.1.1 Collaborations, partnerships and agreements:
8.1.1.2 Acquisition and Mergers:
8.2 Teva Pharmaceutical Industries Ltd.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Product launches:
8.3 Johnson and Johnson
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental &Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Acquisition and Mergers:
8.4 GlaxoSmithKline PLC (GSK)
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Collaborations, partnerships and agreements:
8.4.5.2 Expansion:
8.4.5.3 Approval:
8.5 Pfizer, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Collaborations, partnerships and agreements:
8.5.5.2 Product launches:
8.5.5.3 Acquisition and Mergers:
8.6 Merck & Co., Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Collaborations, partnerships and agreements:
8.6.5.2 Product launches:
8.7 Bayer AG (Bayer Schering Pharma AG)
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 Recent strategies and developments:
8.7.5.1 Collaborations, partnerships and agreements:
8.7.5.2 Product launches:
8.8 Baxter International, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Product launches:
8.9 Bristol-Myers Squibb Company
8.9.1 Company overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expense
8.9.5 Recent strategies and developments:
8.9.5.1 Collaborations, partnerships and agreements:
8.1 Novartis AG
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Segmental and Regional Analysis
8.10.4 Research & Development Expense
8.10.5 Recent strategies and developments:
8.10.5.1 Product launches:
8.10.5.2 Acquisition and Mergers:
LIST OF TABLES
TABLE 1 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 2 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 3 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 4 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 5 NORTH AMERICA FIRST-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 6 NORTH AMERICA FIRST-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 7 NORTH AMERICA SECOND-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 8 NORTH AMERICA SECOND-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 9 NORTH AMERICA THIRD-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 10 NORTH AMERICA THIRD-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 11 NORTH AMERICA FOURTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 12 NORTH AMERICA FOURTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 13 NORTH AMERICA FIFTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 14 NORTH AMERICA FIFTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 15 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 16 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 17 NORTH AMERICA RESPIRATORY TRACT INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 18 NORTH AMERICA RESPIRATORY TRACT INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 19 NORTH AMERICA SKIN INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 20 NORTH AMERICA SKIN INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 21 NORTH AMERICA EAR INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 22 NORTH AMERICA EAR INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 23 NORTH AMERICA SEXUALLY TRANSMITTED INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 24 NORTH AMERICA SEXUALLY TRANSMITTED INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 25 NORTH AMERICA OTHERS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 26 NORTH AMERICA OTHERS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 27 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 28 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 29 NORTH AMERICA INJECTIONS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 30 NORTH AMERICA INJECTIONS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 31 NORTH AMERICA ORAL DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 32 NORTH AMERICA ORAL DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 33 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 34 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 35 NORTH AMERICA BRANDED MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 36 NORTH AMERICA BRANDED MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 37 NORTH AMERICA GENERIC MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 38 NORTH AMERICA GENERIC MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 39 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 40 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 41 USA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 42 USA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 43 USA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 44 USA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 45 USA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 46 USA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 47 USA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 48 USA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 49 USA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 50 USA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 51 CANADA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 52 CANADA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 53 CANADA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 54 CANADA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 55 CANADA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 56 CANADA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 57 CANADA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 58 CANADA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 59 CANADA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 60 CANADA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 61 MEXICO CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 62 MEXICO CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 63 MEXICO CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 64 MEXICO CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 65 MEXICO CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 66 MEXICO CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 67 MEXICO CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 68 MEXICO CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 69 MEXICO CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 70 MEXICO CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 71 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 72 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 73 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 74 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 75 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 76 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 77 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 78 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 79 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 80 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 81 KEY INFORMATION – ABBOTT LABORATORIES
TABLE 82 KEY INFORMATION – TEVA PHARMACEUTICALS INDUSTRIES LTD.
TABLE 83 KEY INFORMATION –JOHNSON AND JOHNSON
TABLE 84 KEY INFORMATION – GLAXOSMITHKLINE PLC (GSK)
TABLE 85 KEY INFORMATION – PFIZER, INC.
TABLE 86 KEY INFORMATION – MERCK & CO., INC.
TABLE 87 KEY INFORMATION – BAYER AG
TABLE 88 KEY INFORMATION – BAXTER INTERNATIONAL, INC.
TABLE 89 KEY INFORMATION – BRISTOL-MYERS SQUIBB COMPANY
TABLE 90 KEY INFORMATION – NOVARTIS AG
TABLE 1 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 2 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 3 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 4 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 5 NORTH AMERICA FIRST-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 6 NORTH AMERICA FIRST-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 7 NORTH AMERICA SECOND-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 8 NORTH AMERICA SECOND-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 9 NORTH AMERICA THIRD-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 10 NORTH AMERICA THIRD-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 11 NORTH AMERICA FOURTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 12 NORTH AMERICA FOURTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 13 NORTH AMERICA FIFTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 14 NORTH AMERICA FIFTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 15 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 16 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 17 NORTH AMERICA RESPIRATORY TRACT INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 18 NORTH AMERICA RESPIRATORY TRACT INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 19 NORTH AMERICA SKIN INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 20 NORTH AMERICA SKIN INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 21 NORTH AMERICA EAR INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 22 NORTH AMERICA EAR INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 23 NORTH AMERICA SEXUALLY TRANSMITTED INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 24 NORTH AMERICA SEXUALLY TRANSMITTED INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 25 NORTH AMERICA OTHERS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 26 NORTH AMERICA OTHERS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 27 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 28 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 29 NORTH AMERICA INJECTIONS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 30 NORTH AMERICA INJECTIONS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 31 NORTH AMERICA ORAL DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 32 NORTH AMERICA ORAL DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 33 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 34 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 35 NORTH AMERICA BRANDED MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 36 NORTH AMERICA BRANDED MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 37 NORTH AMERICA GENERIC MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 38 NORTH AMERICA GENERIC MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 39 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 40 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 41 USA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 42 USA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 43 USA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 44 USA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 45 USA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 46 USA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 47 USA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 48 USA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 49 USA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 50 USA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 51 CANADA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 52 CANADA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 53 CANADA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 54 CANADA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 55 CANADA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 56 CANADA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 57 CANADA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 58 CANADA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 59 CANADA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 60 CANADA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 61 MEXICO CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 62 MEXICO CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 63 MEXICO CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 64 MEXICO CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 65 MEXICO CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 66 MEXICO CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 67 MEXICO CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 68 MEXICO CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 69 MEXICO CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 70 MEXICO CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 71 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 72 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 73 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 74 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 75 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 76 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 77 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 78 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 79 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 80 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 81 KEY INFORMATION – ABBOTT LABORATORIES
TABLE 82 KEY INFORMATION – TEVA PHARMACEUTICALS INDUSTRIES LTD.
TABLE 83 KEY INFORMATION –JOHNSON AND JOHNSON
TABLE 84 KEY INFORMATION – GLAXOSMITHKLINE PLC (GSK)
TABLE 85 KEY INFORMATION – PFIZER, INC.
TABLE 86 KEY INFORMATION – MERCK & CO., INC.
TABLE 87 KEY INFORMATION – BAYER AG
TABLE 88 KEY INFORMATION – BAXTER INTERNATIONAL, INC.
TABLE 89 KEY INFORMATION – BRISTOL-MYERS SQUIBB COMPANY
TABLE 90 KEY INFORMATION – NOVARTIS AG
LIST OF FIGURES
FIG 1 METHODOLOGY FOR THE RESEARCH
FIG 1 METHODOLOGY FOR THE RESEARCH
